Objective response by mRECIST to initial lenvatinib therapy is an independent factor contributing to deep response in hepatocellular carcinoma treated with lenvatinib-transcatheter arterial chemoembolization sequential therapy

Objective response by mRECIST to initial lenvatinib therapy is an independent factor contributing to deep response in hepatocellular carcinoma treated with lenvatinib-transcatheter arterial chemoembolization sequential therapy

Objective: There is limited information regarding the benefits of Lenvatinib-transcatheter arterial chemoembolization (LEN-TACE) sequential therapy for unresectable hepatocellular carcinoma (u-HCC). We compared the efficacy and safety of LEN-TACE sequential therapy to LEN monotherapy and investigate...

Full description

Bibliographic Details
Main Authors: Hidekatsu Kuroda, Takayoshi Oikawa, Masashi Ninomiya, Masashi Fujita, Kazumichi Abe, Kazuo Okumoto, Tomohiro Katsumi, Wataru Sato, Go Igarashi, Chikara Iino, Tetsu Endo, Nobukazu Tanabe, Hiroshi Numao, Shinsaku Fukuda, Katsunori Iijima, Atsushi Masamune, Hiromasa Ohira, Yoshiyuki Ueno, Yasuhiro Takikawa
Format: Article
Language:English
Published: Karger Publishers 2022-02-01
Series:Liver Cancer
Online Access:https://www.karger.com/Article/FullText/522424

Internet

https://www.karger.com/Article/FullText/522424

Similar Items